三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
Wegovy(24年)和Zepbound1年维持率超60%
Wegovy(24年)和Zepbound1年维持率超60%
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:243KB
图片尺寸:1198*891
同报告图片
/
4
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
所属报告:
【国金证券】医药行业研究:GLP-1专题,产品迭代驱动市场扩容,关注靶点、剂型及联合疗法研发进展-251117(38页).pdf
打包全文图表
相关数据
美国约5500万肥胖患者的保险覆盖Wegovy
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
收藏
行业数据
2026-02-06
原图定位
查看详情
司美格鲁肽减重产品Wegovy快速放量(百万美元)
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
收藏
行业数据
2025-06-20
原图定位
查看详情
品牌司美格鲁肽减肥版本(Wegovy)的滴定剂量和价格
fCDliYLph48gICAgICAgfCDms6jlsITlmajop4TmoLwgICB8IOWMheijhSAgICAgICB8IFdBQ+S7t+agvCAgIHwKfC0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tfAp8IDAuMjUgbWcgICAgfCAwLjUgbUwgICAgICAgfCA05pSv6KOFICAgICAgfCAkMSwzNDkuMDIgIHwKfCAwLjUgbWcgICAgIHwgMC41IG1MICAgICAgIHwgNOaUr+ijhSAgICAgIHwgJDEsMzQ5LjAyICB8CnwgMS4wIG1nICAgICB8IDAuNSBtTCAgICAgICB8IDTmlK/oo4UgICAgICB8ICQxLDM0OS4wMiAgfAp8IDEuNyBtZyAgICAgfCAwLjc1IG1MICAgICAgfCA05pSv6KOFICAgICAgfCAkMSwzNDkuMDIgIHwKfCAyLjQgbWcgICAgIHwgMC43NSBtTCAgICAgIHwgNOaUr+ijhSAgICAgIHwgJDEsMzQ5LjAyICB8CgrotYTmlpnmnaXmupDvvJror7rlkozor7rlvrfnvZHnq5k=
收藏
行业数据
2025-03-06
原图定位
查看详情
Saxenda+Wegovy21年销售额合计84亿丹麦克朗,15-21年CAGR62.3%
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
收藏
行业数据
2022-10-11
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
司美/替尔泊肽减重适应症销售占比已提升至 37%。司美格鲁肽、替尔泊肽减重适应症获批时间分别较 2型糖尿病晚 3年半/1年半,但减重适应症销售规模增长迅速,23Q1-25Q2减重适应症销售额在整体销售额中占比迅速从 14%提升至 37%,整体趋势看占比仍将进一步提升。
行业数据
原图定位
当前图表所属:
【国金证券】医药行业研究:GLP-1专题,产品迭代驱动市场扩容,关注靶点、剂型及联合疗法研发进展-251117(38页).pdf
2026年GLP-1行业报告:产品迭代驱动扩容,多靶点与口服剂型重塑格局
【国金证券】医药行业研究:GLP-1专题,产品迭代驱动市场扩容,关注靶点、剂型及联合疗法研发进展-251117
GLP-1类减重药物1-3年维持率约32%/15%/8%
1Q23-2Q25,司美/替尔泊肽减重适应症销售额占比提升至37%
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》